Newsletter | October 2024 Recap

Largest contract signed with Asia-based pharmaceutical company

Samsung Biologics has signed a record-breaking manufacturing deal with an Asia-based pharmaceutical company, a reflection of trusted and sustainable partnerships with our clients to help save patients around the world. By leveraging our innovative biomanufacturing technologies and proven expertise, we will continue our commitment to delivering high-quality biomedicines to the global market. Read more

Accelerating high-dose drug development with S-HiCon?

Samsung Biologics’ S-HiCon? is a high-concentration formulation platform designed to maximize drug delivery and stability for high-dose biopharmaceuticals. By addressing challenges associated with viscosity and protein aggregation, the latest offering can support clients requiring low to ultra-high concentration formulation to develop advanced therapeutics. Read more

Geared towards fusion protein medicines

From cell line development to IND submission, Samsung Biologics has a track record of bringing fusion proteins and other complex molecules to preclinical testing. Deep understanding of a molecule based on a robust in-house database assures clients of timely solutions. Learn more about our CDO services

Optimized operations for reliable biomanufacturing

From real-time monitoring to standardizing processes, Samsung Biologics is committed to minimizing downtime and delivering consistent product quality. Read our latest newsroom story to learn how we achieve seamless biopharmaceutical manufacturing through meticulous facility maintenance and innovative strategies. Learn more about our CMO services

APR Executive interview on Samsung Biologics CDO capabilities

As part of our continued commitment to technology innovation, Samsung Biologics leverages the latest CDO platforms like S-AfuCHO?, S-OptiCharge?, and S-Tensify? to enhance therapeutic efficacy and meet evolving industry needs. Get insights from this interview on how we accelerate development, achieve the highest quality, and flexibly meet clients' goals.

Influence of air-diffusion value shifts on virus-clearance values: safety risk assessment for virus-filter integrity testing in multiround housings

Ensuring viral safety in large-scale manufacturing requires a deep understanding of intricate factors that affect virus-filter performance. In our latest article, we explore how shifts in air-diffusion values impact virus-clearance in multiround housings as well as the key considerations for effective risk assessment.?Read more

Controlling integrated, continuous processes: real-time monitoring with feed-back and feed-forward controls enables synchronization and enhances robustness

Maintaining sterility in continuous bioprocessing can be challenging as multiple connections are required between unit operations. In this article, Soyeon Ahn, Senior Director of Downstream Manufacturing, shares how thorough management of these connections —particularly in perfusion systems— ensures sterility throughout extended production runs. Read more

Prioritizing formulation strategies for temperature-sensitive biotherapeutics

Developing formulations for temperature-sensitive molecules can be challenging due to issues related to solubility, hydrophobicity, and pH shifts. In this roundtable article, Heonchang Lim, Director of Formulation Development, shares insights on how Samsung Biologics conducts rigorous assessments to address such obstacles during the formulation processes. Read more

Manufacturing capabilities for complex biomedicines

Continuous biomanufacturing using N-1 perfusion comes with several benefits, such as improved efficiency and scalability. In this Fierce Pharma article, our MSAT experts Sungkeum Seo and Lalit Saxena discuss the advantages of perfusion technology and the strengths Samsung Biologics offers to reduce production time. Read more

UPCOMING EVENTS